Top Health Tech Companies (10,000+)

Strong Revenue Growth: Revenue is reported to have grown at a robust compound rate over multiple years, with momentum described as accelerating as of 2026. Company updates and industry reporting consistently point to ongoing top-line expansion alongside network scale-up.

Profitability: The company indicates it has been annually profitable since 2023 and cash-flow positive, and it cites performance above the 'Rule of 40' benchmark in 2025. This signals growth paired with financial discipline rather than expansion funded by sustained losses.

Strategic Partnerships: The Care Access Network extends booking into platforms including Amazon Health AI, Google Gemini, Yelp, Healthgrades, and Blue Shield of California. Partner implementations are described as materially increasing booked appointments and expanding available bookable hours, indicating traction beyond the core site.

Strong Revenue Growth: Revenue is growing at double-digit rates, with Q2 2026 up 27% year over year and first-half 2026 up about 25%. Management also raised full-year 2026 guidance to $94–96 million, implying approximately 22–24% growth.

Market Expansion: U.S. activity accelerated, with U.S. analysis volume up 60% year over year in Q2 2026 and major health-system additions. Core genomics customers increased to 542 as of June 30, 2026, from 490 a year earlier.

Customer Loyalty & Retention: Net dollar retention improved to 117% in Q2 2026 (versus 107% a year earlier), indicating greater spending within the installed base. Platform usage also reached a record 115,000 analyses in Q2 2026, up 22% year over year.

Resilient & Sustainable Growth: Revenue has risen at a steady mid- to high-single-digit pace—FY2025 grew 8.3% on a normalized basis, with FY2026 Q1 and Q2 up 7.7% and 7.3% respectively, alongside 3.8% active-customer growth. Management also raised its FY2026 net sales outlook, pointing to continued expansion.

Customer Loyalty & Retention: Autoship sales increased 9.3% in Q2 FY2026 to about $2.82 billion and represented 84.6% of total sales, supporting predictable, repeat purchasing. Sales per active customer also edged up to $602, indicating deepening engagement.

Profitability: Adjusted EBITDA climbed 23.7% in Q2 FY2026 to $226.7 million with a 6.8% margin, and net income rose year over year. These gains indicate improving operating earnings alongside growth.

Investor Backing & Capital Strength: Evidence indicates a $50 million Series D in April 2026 led by Boehringer Ingelheim, following a Series C in March 2025. This ongoing capital access, including dedicated commercialization funding, signals strong financial support for the next phase of growth.

Strategic Partnerships: Evidence indicates deep relationships with Boehringer Ingelheim and Otsuka, alongside new collaborations such as Ultrahuman for migraine-related technology. These alliances are described as enabling development, regulatory progress, and commercialization pathways across multiple programs.

Product Line Growth: Evidence indicates multiple FDA milestones—Rejoyn for major depressive disorder symptoms (2024), CT-132 for episodic migraine prevention (2025), and Motivista/CT-155 for negative symptoms of schizophrenia (2026)—plus expansion into obesity and cardiometabolic disease via acquired assets. These developments broaden the portfolio across therapeutic areas and advance late-stage candidates toward market.

Strong Revenue Growth: Reported $100M in contracted annual recurring revenue and placements on Deloitte Technology Fast 500 and Inc. 5000 indicate substantial multi‑year expansion. These signals point to meaningful top‑line momentum at scale.

Investor Backing & Capital Strength: A $65M growth investment from existing investors provides capital to accelerate expansion and AI adoption. This backing suggests solid financial support and runway.

Innovation-Driven Growth: Adoption of AI agents and co‑pilots across hundreds of providers, plus expansion into new workflows, shows product‑led growth beyond core messaging. FedRAMP authorization further enables innovation to reach federal healthcare settings.

Investor Backing & Capital Strength: Funding activity indicates renewed investor support, with $10 million raised in July 2026 toward a planned $32 million offering following a $28.1 million round in 2023. Cumulatively reported capital of roughly $52.9 million provides resources for rebuilding and expansion.

Market Expansion: Multi-state operations spanning Florida, Michigan, Ohio, Virginia, and Washington and a reported 45,000 attributed lives point to meaningful commercial reach. Company materials describe active launches and team-building across these markets.

Strategic Partnerships: Payer-oriented relationships, including a Carelon collaboration, align the model with health plans and community providers. These arrangements create distribution pathways to hard-to-reach populations within managed-care programs.

Market Expansion: Customer adoption is portrayed as rising from 18,000+ veterinary hospitals in 2022 to 23,000+ by 2024, with a later 25,000+ milestone cited in 2026 across all 50 states. These published milestones indicate broader reach and usage over time, even if exact annual growth rates are not verified.

Strong Hiring & Retention: Workforce estimates point to organizational expansion from 204 employees in 2023 to 343 in early 2026, with ongoing openings across engineering, product, data, and commercial roles. This pattern suggests the company is scaling capacity to support a larger customer base.

Strategic Partnerships: Integrations and industry ties have broadened, including IDEXX Neo, Digitail, DaySmart Vet, and AVMA Direct Connect, alongside other association relationships. These connections embed the platform in day‑to‑day clinic workflows and extend distribution channels.

Market Expansion: Customer adoption is expanding with the platform serving more than one million care‑team members across nearly 6,000 healthcare organizations, and acquisitions extending reach into EMS and smart‑room markets. Feedback suggests the company is broadening its presence across care settings and pre-/post‑hospital workflows.

Product Line Growth: The portfolio is widening through launches such as the CareConduit workflow‑automation platform and an AI‑powered Operator Console, complemented by capabilities gained via Twiage and eVideon. These developments indicate movement beyond secure messaging into a broader healthcare‑orchestration suite.

Strong Market Position & Advantage: Recognition as a Leader in Gartner’s Clinical Communication and Collaboration evaluations underscores competitive standing in its category. Inclusion on the 2026 Inc. 5000 supports the view of multi‑year business momentum.

Strong Revenue Growth: Sacra estimates indicate revenue rose from about $360M in 2023 to roughly $598M in 2024, a sharp increase attributed largely to Ro Body. This points to accelerated top-line momentum rather than mere product proliferation.

Market Expansion: Launches such as the nationwide Wegovy pill on January 5, 2026 and additional obesity-care offerings suggest broader reach across treatment categories and patient segments. Reuters also describes an influx of new customers with the oral Wegovy launch, including men who avoided injections.

Strategic Partnerships: Announcements document direct collaborations with Novo Nordisk on Wegovy and Eli Lilly on Zepbound, alongside a research tie-up with Amgen. These relationships expand access to branded therapies and reinforce distribution relevance in obesity care.

Strong Revenue Growth: Feedback suggests revenue expanded rapidly in recent years, highlighted by inclusion in Deloitte’s 2023 Technology Fast 500 and company-reported acceleration around its 2023 financing. Historical performance signals a strong commercial trajectory through the 2019–2022 period.

Market Expansion: Feedback suggests adoption has broadened across major health systems, including a system-wide Northwell rollout and reported reach to more than 15,000 leaders managing over 300,000 staff by 2026. Customer expansions and multi-site deployments indicate a growing footprint across hospitals and ambulatory sites.

Product Line Growth: Feedback suggests continued investment with AI enhancements, a patient-rounding module, and an AI-powered performance insights feature introduced in 2025. Post-acquisition communications in 2026 underscore ongoing product development and innovation recognition.

Investor Backing & Capital Strength: Investor support is substantial, highlighted by a $65 million Series C led by Goldman Sachs Alternatives and a subsequent $35 million debt facility, providing significant resources for scaling. These financings, together exceeding $100 million in 2026, indicate strong confidence in continued expansion.

Product Line Growth: The offering is broadening with launches such as Sage Detect, Tasking, and Labor, alongside expanded EHR integrations and an entry into skilled nursing. This trajectory moves the company beyond safety monitoring into integrated workflows and workforce/operational management.

Market Expansion: The platform is described as live in hundreds of senior-care communities across 26 states, with portfolio-level rollouts like Navion’s phased deployment across 47 communities. Hiring in sales, account management, deployment, and engineering further supports ongoing commercial expansion.

Investor Backing & Capital Strength: The $31 million Series A led by Oak HC/FT with participation from Norwest, Y Combinator, and others provides resources for deployment, hiring, and AI product development. Feedback suggests this capital has strengthened the company’s ability to scale operations across health systems.

Market Expansion: Deployments span dozens of hospitals, with more than 15 health systems reportedly under multi-year, enterprise-wide contracts and named customers such as MemorialCare, Allina Health, Northwestern Medicine, and others. Feedback suggests the platform manages millions of shifts weekly, indicating meaningful operational footprint.

Product Line Growth: The company is extending beyond staffing and scheduling into patient throughput and capacity optimization, with stated plans to invest Series A capital into AI model development. Feedback suggests this broadened scope positions the platform to address a wider set of hospital operations.

Innovation-Driven Growth: Kora and related AI agents launched in 2025–2026 handled hundreds of thousands of automated billing conversations and expanded into a broader agentic platform, signaling sustained product innovation. The company also advanced AI-driven personalization and new workflows spanning payments, coverage, and support.

Strategic Partnerships: Major health systems and medical groups, including Sanford Health and ApolloMD, have adopted Cedar’s solutions, and integrations expanded with platforms such as Epic and athenahealth. These relationships demonstrate scaling enterprise deployments across complex provider environments.

Market Expansion: Platform scale is described at tens of millions of patients served and over a billion financial interactions, with deployments across health systems, physician groups, and additional provider segments. Industry accolades and ongoing customer wins indicate widening commercial reach.

Product Line Growth: Feedback suggests newer offerings like Pharma Direct and subscriptions are expanding rapidly, indicating momentum beyond the legacy prescription-discount model.

Strategic Partnerships: Feedback suggests deepening relationships with pharmaceutical manufacturers are driving strong growth in Pharma Direct and expanding medication-access programs.

Healthy Cash Flow: Feedback suggests operating cash flow was strong in recent periods, even as total revenue was near flat and segment performance was mixed.

Strong Revenue Growth: Revenue is rising at double-digit rates across 2025 and the first half of 2026, and the 2026 outlook was raised to imply mid‑teens growth. This pattern indicates sustained top‑line expansion rather than a single strong quarter.

Profitability: Earnings are expanding alongside growth, including a return to GAAP profitability and a high adjusted EBITDA margin. Net income growth outpaced revenue in the first half of 2026, underscoring operating leverage.

Customer Loyalty & Retention: Existing customers are spending more, with expansionary net revenue retention and a double‑digit increase in larger ($100K+) client relationships. This points to durable account expansion and cross‑sell momentum.

Strong Revenue Growth: Independent estimates point to a substantial increase in annualized revenue in 2024, reflecting accelerating business volume. While later-year figures are not confirmed, the trajectory suggests meaningful top-line momentum.

Market Expansion: The rollout of covered therapy and psychiatry nationwide, alongside a materially larger provider network, indicates broadening geographic reach and capacity. These moves increase addressable demand and operating scale.

Strategic Partnerships: Collaborations with Amazon Health Services and other digital health platforms extend distribution and can streamline patient intake and insurance workflows. Such partnerships expand the potential patient pipeline even if direct conversion impacts are not disclosed.

Strong Revenue Growth: Reported three-year revenue growth of 1,061% and placement on the 2026 Inc. 5000 underscore rapid top-line expansion. While absolute revenue is not disclosed, the growth trajectory across 2022–2025 is clearly strong.

Investor Backing & Capital Strength: An $80 million Series C in April 2026, bringing total funding above $160 million and a reported $955 million valuation, signals substantial capital support. Participation from established investors and continued financing provide resources for expansion.

Market Expansion: Customer count reportedly grew from more than 200 in 2024 to over 500 by 2026, including 16 of the top 20 MedTech companies. This indicates broadening adoption across both emerging firms and large enterprises.

Strong Revenue Growth: Recurring revenue and contract billings have been rising at low-teen rates since 2022, with expectations for continued double-digit top-line expansion. Reporting also indicates meaningful revenue scale with rapid momentum.

Healthy Cash Flow: Financial analysis points to improving cash generation, with free cash flow expected to increase materially over the near term. This trend signals growing operating efficiency alongside revenue expansion.

Customer Loyalty & Retention: Gross retention remains very high and net revenue retention is described as strong, indicating renewals plus expansion within the existing base. These metrics point to a sticky customer franchise supportive of durable growth.

Strong Revenue Growth: Revenue is described as rising rapidly, surpassing $750 million in 2025 with 45% year-over-year growth, alongside expanding customer reach. The multi-year trend from roughly $400 million in 2023 to $750 million-plus in 2025 points to sustained expansion across the core business.

Profitability: Profitability is reported for eight consecutive years through 2025, with adjusted EBITDA margin improving by five percentage points in 2025. This indicates expansion has been achieved without relying on sustained operating losses.

Diversified Revenue Streams: Growth extends beyond the registry into healthcare, media, retail, and financial services, with Health up 64% and Media up 35% year over year in 2025. Physical showrooms and fulfillment investments further support multiple avenues for monetization.

Strong Revenue Growth: Feedback suggests AKASA reports more than tenfold growth since mid-2024 and nearly sixfold year-over-year inpatient volume processed, indicating rapid commercial traction and usage expansion.

Market Expansion: Feedback suggests deployments have broadened across major U.S. health systems, with a footprint reportedly spanning roughly 500 hospitals and customers representing about 10% of U.S. inpatient discharges.

Investor Backing & Capital Strength: Feedback suggests AKASA has attracted substantial capital, with reported total funding around $200M+, providing resources to scale products and partnerships.